Response Biomedical Closes on $7.7M Private Placement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Response Biomedical said on Wednesday that it has closed on a previously announced C$8 million ($7.7 million) private placement.

More than 13.3 million shares in aggregate were placed to Caduceus Private Investments III, OrbiMed Associates III, and Caduceus Asia Partners, all affiliates of OrbiMed Advisors. Each share was priced at C$0.60.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.